The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1519
ISSUE1519
April 24, 2017
Reduction of Cardiovascular Risk with Evolocumab (Repatha)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Reduction of Cardiovascular Risk with Evolocumab (Repatha)
April 24, 2017 (Issue: 1519)
The results of the recently published FOURIER trial
have shown a reduction in cardiovascular events with
addition of the PCSK9 inhibitor evolocumab (Repatha)
to statin therapy in patients with atherosclerotic
cardiovascular disease...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.